Efalizumab for severe atopic dermatitis: A pilot study in adults

Journal of the American Academy of Dermatology

Volumn 56, Issue 2, 2007, Pages 222-227

  Takiguchi, Rodd ^a   Tofte, Susan ^a   Simpson, Brenda ^a   Harper, Erin ^a   Blauvelt, Andrew ^a   Hanifin, Jon ^a   Simpson, Eric ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CEFALEXIN; DICLOXACILLIN; EFALIZUMAB; PREDNISONE;

ADULT; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; CELL MIGRATION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; LEUKOCYTE MIGRATION INHIBITION; LOOSE FECES; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL GASTROENTERITIS; VISUAL ANALOG SCALE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; CELL MIGRATION INHIBITION; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846038623     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.08.031     Document Type: Article

References (18)

1. Bovenschen H., Seyger M., and van de Kerkhof P. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T cell subsets, epidermal proliferation and differentiation. Br J Dermatol 153 (2005) 72-78
2. Markey A., Allen M.H., Pitzalis C., and MacDonald D.M. T cell inducer populations in cutaneous inflammation: a predominance of T helper-inducer lymphocytes (THi) in the infiltrate of inflammatory dermatoses. Br J Dermatol 122 (1990) 325-332
3. Hoare C., Li Wan Po A., and Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 4 (2000) 1-191
4. Hanifin J., Cooper K.D., Ho V.C., Kang S., Krafchik B.R., Margolis D.J., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines.". J Am Acad Dermatol 50 (2004) 391-404
5. Dustin M., and Springer T. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 107 (1988) 321-331
6. Krueger J., Gottlieb A.B., Miller B., Dedrick R., Garovoy M., and Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T cells and decreases plaque T cells, consistent with inhibition of cutaneous T cell trafficking. J Invest Dermatol 115 (2000) 333
7. Lebwohl M., Tyring S.K., Hamilton T.K., Toth D., Glazer S., Tawfik N.H., et al. A novel targeted T cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
8. Ohmura T., Konomi A., Satoh Y., Hayashi T., Tsunenari I., Kadota T., et al. Suppression of atopic-like dermatitis by treatment with antibody to lymphocyte function-associated antigen-1 in NC/Nga mouse. Eur J Pharmacol 504 (2004) 113-117
9. Hanifin J., and Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 92 Suppl (1980) 44-47
10. Rajka G., and Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol 144 (1989) 13-14
11. Hanifin J.M., Thurston M., Omoto M., Cherill R., Tofte S.J., and Graeber M. The Eczema Area and Severity Index (EASI) assessment of reliability in atopic dermatitis. Exp Dermatol 10 (2001) 11-18
12. Barbier N., Paul C., Luger T.A., Allen R., de Prost Y., Papp K., et al. Validation of the Eczema Area Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 150 (2004) 96-102
13. Jang I.G., Yang J.K., Lee H.J., Yi J.Y., Kim H.O., Kim C.W., et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42 (2000) 1033-1040
14. Berth-Jones J., Takwale A., Tan E., Barclay G., Agarwal S., Ahmed I., et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147 (2002) 324-330
15. Grundmann-Kollmann M., Podda M., Ochsendorf F., Boehncke W.H., Kaufmann R., and Zollner T.M. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 137 (2001) 870-873
16. Berth-Jones J., Graham-Brown R.A.C., Marks R., Camp R.D.R., English J.S.C., Freeman K., et al. Long-term efficacy and safety of cyclosporine in severe adult atopic dermatitis. Br J Dermatol 136 (1997) 76-81
17. Hanifin J.M., Schneider L.C., Leung D.Y.M., Ellis C.N., Jaffe H.S., Izu A.E., et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 28 (1993) 189-197
18. Leonardi C. Efalizumab in the treatment of psoriasis. Derm Ther 17 (2004) 393-400